KLK3 and pachyonychia congenita: Despite the commonly known fact that the serum PSA test does not represent the ideal tumor marker, it is still the most frequently used in the diagnosis and management of PC and the available data indicate that the PSA-based screening can reduce disease-specific mortality [89].